Analysis of variables and interactions among variables associated with a sustained virological response to pegylated interferon alfa-2a plus ribavirin in hepatitis C virus genotype 3-infected patients

摘要: Summary Background The recommended standard therapeutic regimen for chronic hepatitis patients with C virus (HCV) genotype 3 is pegylated interferon plus ribavirin 24 weeks. aim of the present study was to evaluate treatment efficacy and variables predictive success, interactions among contributing a response therapy, utility rapid virological (RVR; week 4 response) predict outcomes in HCV 3-infected routine clinical practice. Methods We prospectively studied baseline during-treatment factors associated sustained (SVR) who received alfa-2a (PEG-IFN α2a) 180μg/week 800mg daily weeks were followed after completion treatment. Results Four hundred twenty-six treated included analysis; 320 (75.1%) showed an SVR. following assessed their ability SVR by means univariable multivariable logistic regression analysis: patient age, sex, pre-treatment viral load, alanine aminotransferase (ALT), body mass index (BMI), RVR. – ALT, RVR statistically significant predictors ( p 5 IU/ml; OR 3.4, 95% CI 1.87–6.25; 40 years more pronounced than those aged ≤40 years: 81.1% >40 achieved had SVR, whereas only 7.5% did not achieve Conclusions independent variable that Moreover older (>40 years) are likely have while do high load (>8 × 10 IU/ml) unlikely